S5B-16162-58818
4 vaccinations
2 coded responses
39 check-ins
1 free-text entry
2 call cases
- Sex
- Female
- Age at first dose
- 46-50
- ZIP prefix
- 152 / PA
- Registered
- 2021-02-26
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-26
Registered in v-safe
-
2021-02-26
Dose 1 — Pfizer-BioNTech
- 2021-02-26
-
2021-02-27
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-02-28
- 2021-03-01
- 2021-03-02
- 2021-03-03
- 2021-03-04
- 2021-03-05
- 2021-03-12
-
2021-03-19
Dose 2 — Pfizer-BioNTech
- 2021-03-19
-
2021-03-20
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain, Itching · Fever · Headache, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
- 2021-03-21
-
2021-03-22
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-03-23
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-03-24
- 2021-03-25
- 2021-03-26
- 2021-04-02
- 2021-04-09
- 2021-04-16
- 2021-04-23
- 2021-04-30
- 2021-06-18
- 2021-09-17
-
2021-09-22
Dose 3 — Pfizer-BioNTech
- 2021-10-02
- 2021-10-06
- 2021-10-13
- 2021-10-20
- 2021-10-27
- 2021-11-03
- 2021-12-22
-
2022-03-23
Survey response — 6 months, dose 3MedDRA: Thyroid disorder — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Thyroid issuesMedDRA releases: 2024-11 · check-in free text available
-
2022-03-23
Report sent to call center — 6 months, dose 3Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-24
-
2022-07-23
Dose 4 — Pfizer-BioNTechCo-administered: Tetanus
- 2022-08-10
- 2022-08-13
- 2022-08-22
- 2022-08-27
- 2022-09-03
- 2022-10-22
-
2023-01-21
Survey response — 6 months, dose 4MedDRA: SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationMedDRA releases: 2024-11
-
2023-01-21
Report sent to call center — 6 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2023-01-23
- 2023-01-23
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-26 | Pfizer-BioNTech | |
| 2 | 2021-03-19 | Pfizer-BioNTech | |
| 3 | 2021-09-22 | Pfizer-BioNTech | No |
| 4 | 2022-07-23 | Pfizer-BioNTech | Tetanus |
Call center
2 call center cases
2 unsuccessful
Free text
Release 11 — 6 months, dose 3
Symptoms: Thyroid issues
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SD | Thyroid disorder | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release